Coverage

Serbia: what the RFZO lists from 11 July 2026 pay for in lung cancer

Lists B and C of the RFZO health insurance fund apply in the version from 11 July 2026. We checked which lung cancer medicines they include, and on what conditions.

  • Published on
  • Serbia
  • Checked against the source by the hub team on 16 November 2026

Most important in brief

  • For EGFR and ALK, the main tablets are on the list; for lung cancer without these changes, immunotherapy with pembrolizumab or atezolizumab.
  • No medicine for KRAS G12C, ROS1, RET, MET, NTRK or HER2 is on the list.
  • Three doctors at one of the seven named hospitals propose the treatment; the RFZO commission approves it.

What applies now

Lists B and C of the RFZO health insurance fund, valid from 11 July 2026 · List C (PDF), List B (PDF) · checked on 16 November 2026

Test resultMedicineWhat for (simplified)
EGFR
osimertinib
First treatment for advanced NSCLC with an EGFR mutation; with T790M after an earlier EGFR tablet; after complete surgery (stage IB–IIIA, exon 19 or L858R).
EGFR
gefitinib, erlotinib, afatinib
First treatment, stage IIIb/IV, good general condition. Erlotinib also later in adenocarcinoma.
ALK
alectinib, brigatinib
First treatment for advanced ALK-positive NSCLC.
no EGFR or ALK
pembrolizumab
First treatment: alone if PD-L1 is 50% or more, with chemotherapy if PD-L1 is lower. A few cycles first, then continued only if it works.
no EGFR or ALK
atezolizumab
First treatment alone if PD-L1 is high, or with chemotherapy; also after chemotherapy.
Chemotherapy
carboplatin, cisplatin, docetaxel, paclitaxel, gemcitabine, vinorelbine, pemetrexed
Lists B and C. Everything on these lists is fully paid by the fund.

How to get the treatment

Three doctors from one of the hospitals below propose the treatment, and the RFZO commission approves it. The list names these hospitals:

  • Institut za onkologiju i radiologiju Srbije (Beograd)
  • Klinika za pulmologiju, UKC Srbije (Beograd)
  • KBC Bežanijska kosa (Beograd)
  • Vojnomedicinska akademija (Beograd)
  • Institut za plućne bolesti Vojvodine (Sremska Kamenica)
  • Klinika za plućne bolesti, UKC Niš
  • UKC Kragujevac

Not on the list

Lorlatinib, crizotinib and durvalumab; no medicine against KRAS G12C, ROS1, RET, MET, NTRK or HER2. Dabrafenib and trametinib are listed for melanoma only.

What is not publicly known

A new regulation from July 2026 may come with newer tables. Whether biomarker tests are always paid is not stated in these lists.

What this means for you

If you are treated in Serbia and your report shows EGFR or ALK, the main tablets are paid. Without these changes it is usually immunotherapy. A team of doctors at one of the named hospitals applies; ask whether your hospital is one of them.

For KRAS G12C, ROS1 and the rarer changes, no medicine is on the list. Ask your care team what other ways there are.

More under Costs

Sources

  1. RFZO: Lista C, primena od 11.07.2026
  2. RFZO: Lista B, primena od 11.07.2026

Source checked on 16 November 2026

All updates